SG/PUT/BRISTOL-MYERS SQUIBB/55/0.1/21.03.25

SG/PUT/BRISTOL-MYERS SQUIBB/55/0.1/21.03.25 Stock

DE000SU7K520

Market Closed - Boerse Frankfurt Warrants 15:37:01 2024-06-14 EDT
1.33 ^EUR	+1.53%

Current month	-2.21%
1 month	+29.13%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/PUT/BRISTOL-MYERS SQUIBB/55/0.1/21.03.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	06-14	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	06-13	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	06-13	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	06-13	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-14	1.33	+1.53%
24-06-13	1.31	+7.38%
24-06-12	1.22	+3.39%
24-06-11	1.18	-2.48%
24-06-10	1.21	-7.63%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 03:37 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SU7K52
ISIN	DE000SU7K520
Date issued	2024-01-29
Strike	55 $
Maturity	2025-03-21 (279 Days)
Parity	10 : 1
Emission price	0.77 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.42 €
Lowest since issue	0.49 €
Spread	0.01 €
Spread %	0.74%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company